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A B S T R A C T
Synthesized cyclic perylene diimide, cPDI, showed the binding constant of 6.3× 106M−1 with binding num-
ber of n= 2 with TA-core as a tetraplex DNA in 50mM Tris-HCl buffer (pH = 7.4) containing 100mM KCl
using Schatchard analysis and showed a higher preference for tetraplex DNA than for double stranded DNA
with over 103 times. CD spectra showed that TA-core induced its antiparallel conformation upon addition of
cPDI in the absence or presence of K+ or Na+ ions. The cPDI inhibits the telomerase activity with IC50 of
0.3µM using TRAP assay which is potential anti-cancer drug with low side effect.
© 2017.
1. Introduction
The terminal of DNA in human chromosomes are composed of
tandem G-rich d(TTAGGG) repeats up to 2–10kb.1 These telom-
eric DNA terminals are a single-stranded 3′ overhang having around
100–200 nucleotides. This terminal overhang can form G-quadru-
plexes by self-associating through Watson-Crick and Hoogsteen hy-
drogen bonding.2 Telomeric DNA contains the Shelterin nucleopro-
tein complex, which protects chromosomal ends from end-to end fu-
sions and DNA damage. Telomerase enzyme adds d(TTAGGG) re-
peats to the 3′ terminus actively and extends the length of telomeric
DNA, conforming chromosomal integrity after each cell cycle.3 Gen-
erally, telomerase is up-regulated in 85% of human cancers, and has
negligible activity in somatic cells. Thus, for the development of new
anticancer drugs and therapeutic applications these guanine-rich se-
quences have become a very important target.4 Many approaches have
been developed for inhibition of telomerase. Albeit indirect strategy
for telomerase inhibition involves the use of small molecules to ther-
mally stabilize G-quadruplex structures formed from these telomeric
d(TTAGGG) repeats. The goal of these small molecules is to displace
the telomerase and/or other key telomeric proteins such as hPOT1.5
The potential anti-cancer and therapeutic agents are small molecules
that stabilize the G-rich single-strand DNA overhang into G-quadru-
plex.6
During past few years numerous small molecules have been de-
veloped to interact with G-quadruplex DNA. Some of these com
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pounds have also established the enzyme telomerase inhibition.7 Gen-
erally G-quadruplex binding ligands are polycyclic, aromatic ligands
substituted at multiple positions.8 In many cases, the selectivity for
G-quadruplex DNA over double-stranded DNA of the ligands so far
identified is often less than ideal. This low selectivity leads to non-
specific cellular cytotoxicity.9 The major goal for G-quadruplex lig-
ands is to increase the selectivity for G-quadruplex DNA over dou-
ble-stranded DNA and correspondingly to reduce cytotoxicity in or-
der to use these molecules as telomerase inhibitors, or as biolog-
ical probes for in vivo detection of G-quadruplex. Therefore it is
necessary to understand the mechanism of observed selectivity for
G-quadruplex interactive ligands to logically design ligands with im-
proved G-quadruplex selectivity.10 By using the DOCK shape-com-
plementarity scoring algorithm, previously it has been identified that,
3,4,9,10-perylenetetracarboxylic acid diimides (PTCDIs) are poten-
tial G-quadruplex interactive molecular scaffolds.11 A perylene di-
imide PIPER facilitates the formation of G-quadruplex DNA from
single-strand DNA12 as well as certain duplex oligonucleotides. The
perylene diimide N,N'-bis(3-(dimethy-
lamino)propyl)-3,4,9,10-perylenetetracarboxylic acid diimide is found
to precipitate in binding trace amounts of calf thymus DNA, provid-
ing evidence for double-stranded DNA binding also.13 These planar,
heterocyclic aromatic perylene diimides are known to self-assemble
through stacking interactions.14 Previously reported that this aggregate
formation may occur at a nucleation site as in the case of ligands ag-
gregating on DNA templates. In another way, these ligands may also
aggregate separately from the DNA in solution, resulting in an aggre-
gate capable of binding DNA or sometimes hiding ligand from lig-
and-DNA interactions.15
https://doi.org/10.1016/j.bmc.2017.10.014
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We have been developing cyclic naphthalene diimide derivatives,
where cNDI is typical example of this series.16–20 We found that linker
chain of cNDI diminished affinity for double stranded DNA keep-
ing binding affinity for tetraplex DNA (Fig. 1). The cNDI was more
specific for the tetraplex DNA, but the binding affinity has not im-
proved.16–19 The model perylene diimide PIPER having linear alkyl
chain with piperidine as terminal moiety has more binding affinity
for tetraplex DNA, but the selectivity over the dsDNA was not im-
proved. In an attempt to further increase the selectivity and affinity of
the ligand with tetraplex DNA, in the present work we have synthe-
sized the cyclic perylene diimide which has extended aromatic core
compared to naphthalene diimide and the interaction studies of cPDI
with tetraplex DNA and double stranded DNA were studied. This
cyclic chain in perylene diimide prevents the traditional aggregation
that takes place in perylene diimides, leading to only to the aggrega-
tion of two molecules with J-aggregation. Interestingly the cPDI has
shown the 2-fold improved affinity with the tetraplex DNA and lower
affinity with the double stranded DNA by half, emerging it as more
efficient anticancer drug.
2. Material and methods
2.1. Reagents
Calf thymus DNA (ε, 12,824M−1 cm−1),21 was obtained from
Sigma Aldrich (St. Louis, MO). The following oligonucleotides were
custom-synthesized from Genenet (Fukuoka, Japan): TA-core;
5′-TAG GGT TAG GGT TAG GGT TAG GG-3′(ε,
236,500 M−1 cm−1), HP-27; 5′-GCG ATT CTC GGC TTT GCC GAG
AAT CGC-3′(ε, 245,800 M−1 cm−1), dsOligo; 5′-GGG AGG TTT
CGC-3′ (ε, 114,000M−1 cm−1) and 5′-GCG AAA CCT CCC-3′ (ε,
108,600 M−1 cm−1). The TA-core, HP-27, ds-oligo were annealed in
the measurement buffer before use. The 3.0M Potassium Acetate (pH
5.5), 2.0M KCl, and 5.0M NaCl aqueous solutions were obtained
from Life Technologies (Carlsbad, CA). 1.0M Tris–HCl (pH 7.4)
buffer was obtained from Sigma–Aldrich (St. Louis, MO).
2.1.1. Synthesis of cPDI
cPDI was synthesized according to Scheme 1
Fig. 1. Strategy of G-quartet specific ligand based on cyclic perylene diimide.
Scheme 1.
2.1.1.1. N,N′-bis{[3-(3-tert-Butoxycarbonylaminopropyl)-piperazin-
1-yl]propyl} perylene-3,4,9,10-tetracarboxylic acid diimide (PDI-p-
Boc)
{3-[4-(3-Aminopropyl)piperazin-1-yl]propyl}-carbamic acid
tert-butyl ester (p-NH2(Boc)) was synthesized as described previ-
ously.20 1.94g (6.45 mmol) of p-NH2(Boc) and 200mL of Toluene
(Wako Pure Chemical Industry, Ltd., Tokyo, Japan) were added to
3,4,9,10-Perylenetetracarboxylic dianhydride (Tokyo Chemical In-
dustry Co., Ltd., Tokyo, Japan) 1.01g (2.58 mmol). It was refluxed for
10h. After allowing cooling to room temperature, the solvent was dis-
tilled off with an evaporator to obtain a red solid. To the solid after
ultrasonic irradiation for 1h, suction filtration was carried out. The re-
sulting red solid was dried under vacuum (0.99g, Yield 77%).
1H NMR (500MHz, CDCl3, δ ppm) 1.59 (m, 4H), 1.94 (m, 4H),
2.30 (t, 8H), 2.51 (t, 16H), 3.13 (d, 4H), 4.26 (t, 4H), 5.42 (br s,
2H), 8.55 (d, 4H), 8.63(d, 4H); MALDI-TOFMS (positive mode,
α-cyano-4-hydroxycinnamic acid (α-CHCA)) m/z = 958.373 (theory
for C54H68N8O8 + H
+ = 958.189).
2.1.1.2. N,N′-Bis{[3-(3-Aminopropyl)piperazin-1-yl]propyl}-
perylene-3,4,9,10-tetracarboxylic acid diimide (PDI-p-NH2)
In an eggplant flask, PDI-p-Boc 0.176g (0.184 mmol) and 10mL
dichloromethane (Wako Pure Chemical Industry, Ltd.) was added
and dissolved therein, and 5mL (65.3 mmol) of trifluoroacetic acid
(TFA, Wako Pure Chemical Industry, Ltd.) was added to it. It was
stirred for 3h at room temperature. Then the reaction mixture was
evaporated under reduced pressure to obtain a dark red solid. This
solid was dissolved in small amount of dichloromethane and added
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dropwise to 500mL of ethylacetate for reprecipitation. Suction filtra-
tion was carried out, and vacuum drying was carried out to obtain
product as maroon color solid (0.25 g, Yield, 88%)
1H NMR (500 MHz, CDCl3, TMS, δ ppm) 1.95 (m, 4H), 2.28
(d, 4H), 2.80 (t, 4H), 3.00 (m, 8H), 3.30–3.50 (m, 20 H), 4.21 (t,
4H), 7.84–7.99 (m, 8H); MALDI-TOFMS (positive mode, α-CHCA)
m/z = 760.041 (theory for C44H52N8O4 + H
+ = 757.953).
2.1.1.3. Synthesis of cPDI
In an eggplant flask, 0.300g (0.208 mmol) of PDI-p-NH2·6
CF3COOH, 0.054g (0.312 mmol) of Pimelic acid (Tokyo Chemical
Industry Co., Ltd.) and 0.237g (0.625 mmol) of HATU (1-[Bis (di-
methyl amino) methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium-3-ox-
idhexafluoro phosphate) (Watanabe Chemical Industries, Ltd., Hi-
roshima, Japan) were dissolved in 200mL of N,N′-dimethylformamide
(DMF). Then a solution obtained by dissolving 4mL of N,N-Diiso-
propylethylamine in 50mL of DMF was dropped in the above solu-
tion through dropping funnel over 1h with stirring. After 24h, the
stirring was terminated and the solvent was removed with an evap-
orator. Thereafter, the crude product was purified by silica gel col-
umn chromatography (developing solvent: CHCl3: MeOH: diethy-
lamine = 10:0.1:0.02) after distilling off the solvent, it was dried un-
der vacuum and the product was collected as a red color solid (9.1mg,
Yield, 5%). The reverse-phase HPLC using an Inertsil ODS-4 column
(inner diameter, 5μm; size, 4.6× 250mm2, GL Science Inc., Tokyo,
Japan) was carried out in a gradient mode at a flow rate of
1.0mL min−1, where the concentration of acetonitrile was changed lin-
early from 21% to 70% in water containing 0.1% trifluoroacetic acid
over 25min at 40°C (Fig. S1).
1H NMR (500 MHz, CDCl3, δ ppm, Fig. S2) 0.88 (t, 2H), 1.15 (m,
8H), 1.86–2.30 (m, 24H), 2.53 (t, 4H), 2.73 (t, 4H), 2.99 (t, 4H), 4.39
(t, 4H), 6.35 (br s, 2h), 8.67 (d, 4H), 8.60 (d, 4H); MALDI-TOFMS
(positive mode, α-CHCA, Fig. S3) m/z = 882.343 (theory for
C51H60N8O6 + H
+ = 882.464).
2.2. UV–vis measurements
Small amount of the 150μM TA-core or 3mM-bp Calf Thymus
DNA (CT-DNA as dsDNA) in 50mM Tris-HCl (pH 7.4) contain-
ing 0.10M KCl was added to 5.0μM cPDI in 50mM Tris-HCl (pH
7.4) containing 0.10M KCl, and their absorption spectrum change was
monitored at 25°C. The observed spectrum changes at 500nm were
rearranged with Scatchard plot as the following equation,22
where ν, L, n, and K refer to the saturation fraction as the amount
of bound ligand per added DNA, amount of unbound ligand, binding
number of ligand per one DNA molecule, and binding affinity, respec-
tively. The K and n values were obtained from Eq. (1), calculated us-
ing the ν and L in the different ratio of ligand and DNA concentration
obtained using the non-linear least-squares method. For dsDNA, nK
values were obtained using the Benesi-Hildebrand method by using
the equation,23
2.3. Circular dichroism (CD) measurements
2.3.1. CD spectra measurements
CD spectra of the 1.5μM TA-core were measured in 50mM
Tris-HCl (pH 7.4) containing 0.10M KCl at 25°C, in the presence of
0μM to 7.5μM of cPDI in case of TA-core and 0μM to 10μM in
case of CT-DNA, at a scan rate of 50nm/min, using a Jasco J-820
spectropolarimeter (Tokyo, Japan) with the following conditions: re-
sponse, 4 s; data interval, 0.2nm; sensitivity, 100mdeg; bandwidth,
2nm; and scan number, 4 times.
2.3.2. Tm measurements
Melting curves of 1.5μM TA-core at 288nm was measured in
50mM Tris-HCl (pH 7.4) containing 20mM KCl or 20mM NaCl in
the absence or presence of 1.5μM of cPDI using a Jasco J-820 spec-
trophotometer equipped with a temperature controller with the fol-
lowing condition: response; 100mdeg, temperature gradient; 60°C/h,
response; 1 s; data collecting interval; 0.5 °C, and bandwidth; 1nm.
Three ml of total volume was used in the cell with 1cm of light path
length.
Melting curves of 1.5μM dsOligo at 283nm was measured in
50mM Tris-HCl (pH 7.4) containing 20mM KCl in the absence or
presence of 1.5μM of cPDI.
2.4. Isothermal titration calorimetry (ITC)16
TA-cores (10 μM) in 50mM AcOK-AcOH (pH 5.5) or
AcONa-AcOH (pH 5.5) were heated at 95°C for 10min and sub-
sequently cooled to 25°C at 1.0 °C/min before being used for ITC.
Binding studies were performed using low volume Nano ITC (TA
instruments, USA), with a cell volume of 170 μL, at 25°C. All so-
lutions were degassed for 10min before use. For cPDI, the sample
cell was filled with the 10μM TA-core in 50mM AcOK-AcOH (pH
5.5) or AcONa-AcOH (pH 5.5), and 1.96μL of 100μM cPDI 50mM
AcOK-AcOH (pH 5.5) or AcONa-AcOH (pH 5.5) was added into the
thermo stated cell repeatedly using a syringe.
The resulting data were analyzed by independent model using
NanoAnalyze software (TA instruments).
2.5. Topoisomerase I assay16
Typically, 0.025μg/μL pUC19 plasmid DNA (TAKARA Bio,
Tokyo, Japan) was incubated with 0.25 units/μL of human Topoiso-
merase I (Topo I, TAKARA Bio) enzyme containing 0.01% BSA for
5min at 37°C in 1× Topo I reaction buffer (35 mM Tris-HCl (pH 8.0),
72mM KCl, 5.0mM MgCl2, 5.0mM Dithiothreitol, 5.0mM Spermi-
dine). The appropriate amount of compound cPDI was then added and
the reaction mixture was incubated for a further 1h at 37 °C. The re-
action was finished by adding 2.0μL of 10% SDS to reaction mix-
ture (20 μL). Then, 0.5 μL of 20mg/mL proteinase K was added and
incubated for 15min at 37°C. After that 100μL of 1× TE (10 mM
Tris-HCl, 1mM EDTA, pH 8.0) was added and two subsequent ex-
tractions were carried out using following mixtures: one of phenol/
chloroform/isoamyl alcohol (25:24:1) and second of phenol/chloro-
form (24:1). Then remaining aqueous DNA sample was run on an
agarose gel (1%) at 18V for 3.5h, stained with Gel Star (TAKARA
Bio) and photographed.
(1)
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2.6. TRAP assay16
A TRAP assay was performed by following published literature
using a TRAPeze kit (EMD Millipore) according to the manufactur-
er's instructions. Lysate protein was treated using the TRAPese kit's
positive-control cell according to the manufacturer's instructions. The
telomerase reaction solution (12.5 μL) consisted of 20mM Tris-HCl,
pH 8.3; 1.5mM MgCl2; 63mM KCl; 0.05% Tween 20; 1.0mM eth-
yleneglycol-bis(β-aminoethyl)-N,N,N′,N′- tetraacetic acid; 1× dNTP
mixture; 1× TS primer; 1× primer mix; 2.0 units of Taq polymerase;
250 cells of the lysate protein. The mixture was added to freshly
prepared cPDI solutions with the concentration ranging 0, 0.5, 1.0,
3.0, 5.0, 7.0, 10.0, 15.0, 20.0μM. Reactions were run under the fol-
lowing conditions: 1× 30°C, 1h; 35× (95°C, 1min, 62°C, 1min,
72°C, 1min); 1× 72°C, 10 min. Gel electrophoresis on 12.5% poly-
acrylamide prepared in 1.25× TBE (111 mM Tris base, 111mM bo-
rate, and 2.5mM ethylenediaminetetraacetic acid, pH 8.0) was run at
200V for 1h in 0.7× TBE. After electrophoresis, the gel was stained
with 1× GelStar® Nucleic Acid Stain in 1× TBE (89mM Tris base,
89mM borate, and 2.0mM ethylenediaminetetraacetic acid, pH 8.0)
for 30min and photographed. The resulting data were analyzed ac-
cording to the manufacturer's instructions.
3. Results and discussions
3.1. Binding affinity of cPDI with TA-core and CT-DNA by UV–vis
absorption studies
The UV–vis absorption spectra were investigated to obtain the
binding constant and the number of binding molecules for the in-
teraction of cPDI with different DNA forms such as human telom-
ere (TA-core) and calf thymus DNA (CT-DNA). TA-core (5′-TAG
GGT TAG GGT TAG GGT TAG GG-3′) was known to form the
hybrid-I structure in aqueous solution containing KCl.25,26 and thus
this sequence was used in the binding analysis without any complex-
ity. Fig. 2A, B shows a representative spectrophotometric titration of
cPDI with human telomeric G-quadruplex DNA (TA-core) in K+ ion.
In order to study the selectivity of ligand, we also investigated the
interaction of cPDI with dsDNA. It shows the absorption peaks at
500nm and 550nm. Addition of increasing amounts of G-quadruplex
DNAs (0 µM–15.7µM) to cPDI showed large hypochromicities (42%
at 500nm) and a significant red shift of 13nm at 500nm peak and a
hyperchromic shift at 550nm (55%) was observed. We observed isos-
bestic points at 510nm and 520nm of cPDI for G-quadruplex DNAs
and duplex DNA, respectively. The presence of isosbestic points in-
dicated the equilibrium between the bound and free ligand. Upon the
addition of increasing amounts of dsDNA (0µM–323.4µM) to cPDI,
larger hypochromic shifts (50%) and very small red shifts (8 nm) at
Fig. 2. Spectral shifts of cPDI on titration with (A) 0µM to 15.7µM of TA-core (B) 0µM to 323.4µM of CT-DNA in 50mM Tris-HCl (pH 7.4) containing 100mM KCl. (C)
Scatchard plots for binding of cPDI to TA-core (D) Benesi-Hildebrand plot for binding of cPDI to dsDNA.
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500nm and small hyperchromic shift (29%) at 550nm were observed.
These large changes in the hyperchromic and hypochromic shift with
the addition of tetraplex DNA attribute that cPDI is effectively bind-
ing to TA-core than the CT-DNA suggesting this ligand is not a good
dsDNA binder (Fig. 2B). The Scatchard plot representing the bind-
ing between cPDI and TA-core (KCl) is presented in Fig. 2C. The
Scatchard plot was analyzed by the McGhee-von Hippel Scatchard
equation16,22 The solid line in Fig. 2C represents the best fit of the
experimental value to the McGhee-von Hippel equation. For dsDNA
saturation of binding curves was not achieved, therefore, estimation
of K values using the Scatchard equation was impossible. However,
nK values were estimated using the Benesi-Hildebrand method
(Fig. 2D).16,23 In the presence of potassium ions cPDI binds to
TA-core more efficiently than to dsDNA. The intrinsic binding con-
stants (K) of cPDI to G-quadruplexes DNA and dsDNA are summa-
rized in Table 1.
3.2. CD experiments
Circular dichroism is a typical method to differentiate between dif-
ferent conformations or secondary structures of G-quadruplex DNA.
We used circular dichoroism to further characterize the binding of the
cPDI and TA-core quadruplex interaction. As shown in Fig. 3A, after
addition of the CD spectrum of TA-core shows hybrid structure with a
positive band at 290nm and a negative band at 240nm. The G-quadru-
plex was then titrated with cPDI. As shown in Fig. 3B, incremental
addition of cPDI from 0µM to 7.5µM to the quadruplex resulted in
large increase in the intensities of negative band at 240nm and 290nm
in the positive band. However, induced CD signals were observed
at 550nm, which corresponds to the chromophore cPDI absorption
wavelength. The appearance of induced CD as well as the changes in
the positive intensity at 290 nm and negative intensity 240nm suggests
the binding of cPDI to this quadruplex and stabilization of antipararell
structure of G-quadruplex DNA.26–28 On the other hand after addition
of Na+ the TA-core obtained the basket structure. After the addition
of cPDI from 0µM to 4.5µM the structure converted to antipararell
structure (Fig. 3B). When there is no metal, the TA-core with random
coil structure also converted to antipararell structure upon addition of
cPDI from 0 to 5 equivalents (Fig. 3C). This shows that cPDI stabi-
lize the antipararell structure of TA-core in all the cases with K+, Na+
and also no metal (Fig. 3E). In contrast to the TA-core, when titrated
with ds-oligo from 0µM to 10µM with cPDI, there is no change in
the intensities of the 250nm positive band and 280nm negative bands.
Moreover we did not observe any induced signal in case of ds-oligo
DNA as shown in Fig. 3D. This indicates that the cPDI has very low
binding affinity towards ds-oligo and selectively bind to the tetraplex
DNA.
3.3. Thermal stability of DNAs
Thermal stabilization of G-quadruplex DNA and dsDNA in the
presence of cPDI was studied using DNA melting temperature mea
Table 1
Comparison of binding constants of cPDI and cNDI with TA-core and CT-DNA.
Ligand 10−6 K/M−1
TA-corea CT-DNAb
cPDI 6.3± 0.4 0.007± 0.0001
cNDI 3.7± 0.2 0.039± 0.001
a K determined with Scatchard method.
b K determined with Benesi-Hildebrand method.
surements. Thermal melting of hybrid type telomeric quadruplex
DNA (TA-core) and ds-oligo as double stranded DNA were monitored
at 288nm or 283nm in the presence of K+ and Na+ (Fig. S4). The Tm
value was observed around 53.0°C for TA-core without cPDI in pres-
ence of K+. We observed that the interaction of cPDI with telomeric
DNA quadruplex enhanced the stability by 21°C for TA-core (Table
2). In the previously reported literature it has been proven that thermal
melting increases after addition of base to oligonucleotides.16–20 After
the addition of a 1-fold cPDI concentration, an increase (up to 21°C)
in thermal stability was observed (Table 2). In presence of Na+ the
Tm was 37.5°C and TA-core found to be stabilized by 14°C. The Tm
value was observed around 51.0°C for dsOligo without cPDI in pres-
ence of K+. After addition of 1-fold, 2-fold and 3-fold cPDI the ther-
mal stability of DNA was not changed considerably (Fig. S4, C). As a
result the interaction of cPDI with TA-core DNA increases the stabil-
ity significantly where as it has no stabilizing effect on the ds-DNA.
These results give emphasis to the fact that cPDI selectively stabi-
lizes telomeric quadruplex DNA over dsDNA. In comparison with our
previous report,16–19 compound cPDI showed high stabilizing effect
where as cNDI shown the stabilization effect with ΔTm of 3°C. Ac-
cording to the above result, we can conclude that cPDI preferably
stabilizes telomeric quadruplex DNA than ds-Ologo DNA. cPDI has
more stabilization effect than cNDI reported previously indicating that
cPDI as an efficient ligand for the G-Quadruplex DNA.
3.4. Isothermal titration calorimetry (ITC)
Thermodynamic parameters of the interaction between cPDI and
the TA-core, which is known as a hybrid-type G-quartet structure,
were measured by the ITC titration of 100μM cPDI with the 10μM
TA-core in 50mM AcOK-AcOH (pH 5.5) or 50mM AcONa-AcOH
at 25°C. In the ITC experiment cPDI was interacted with different
DNAs such as TA-core and HP-27 (Fig. 4A, B). A small portion of
150μM cPDI in 0.10M AcONa-AcOH containing 0.10M NaCl and
AcOK-AcOH containing 0.10M KCl (pH 5.5) was added to the same
buffer containing the 10μM TA-core and all other types of DNAs.
Very stable thermal changes were observed in the parameters such as
enthalpy, entropy and free energy in cPDI. Double stranded DNA has
not shown considerable binding interactions as TA-core. All the ther-
mal and binding parameters of cPDI with various DNAs have been
tabulated in Table 3. The binding ratios of the ligand to tetraplex DNA
was 2:1 in the presence of NaCl. The 2:1 ratio observed in the ITC
and the UV studies suggested that the stacking of the ligand to the up-
per and lower G-quartet aromatic planes takes place with the aggre-
gation of ligand in J-aggregation manner.29 The ΔH and TΔS values
in the binding process of cPDI with a TA-core were −6.84 kcal mol−1
and 1.38kcal mol−1, respectively. This suggested the stable complex
formation of cPDI with TA-core through the additional interaction of
their linker chains such as hydrogen bonding. The thermal changes in
the presence of both Na+ and K+ ions are almost same and confirm the
formation of stable complex with TA-core. And in both cases there is
no evidence of complex formation with HP-27. After addition of K+,
Na+ TA-core obtained the hybrid, basket conformations respectively.
Upon increasing the addition of cPDI in both cases the ligand stabi-
lizes the TA-core to the hybrid conformation. Thus, cPDI showed sig-
nificant contributions of enthalpy and entropy, and might show effec-
tive contribution of the π-π-stacking interaction and dehydration af-
ter complex formation. And it is being formed a stable complex with
tetraplex DNA.
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Fig. 3. CD titration of TA-core with cPDI under 50mM Tris-HCl buffer (pH 7.4) containing (A) 100mM KCl, (B) 100mM NaCl, (C) no salt and (D) with CT-DNA.
3.5. Topoisomerase I assay
Topoisomerase-based gel assays have been widely used to evalu-
ate compounds for their ability to intercalate into DNA. Cyclic pery
lene diimide cPDI did not show any unwinding of super coiled plas-
mid DNA, even using excess amounts of cPDI in the Topoisomerase I
assay. We could not easily observe supercoiling of plasmid DNA un-
der interactions with cPDI over a range of 0µM to 40µM (Fig. 5).
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Table 2
Melting temperatures of cPDI with TA-core and dsOligo.
DNA Metal cation Tm ΔTm/°Cb
+ cPDI
TA-core K+ 53.0 74.0 21.0
Na+ 37.5 51.5 14.0
dsOligo K+ 51.0 50.0 −1.0
a1.5μM TA-core or dsOligo in 50mM Tris-HCl (pH 7.4) and 20mM KCl or NaCl.
b[cPDI]: [DNA] = 1: 1 in 50mM Tris-HCl (pH 7.4) and 20mM KCl or NaCl.
Fig. 4. ITC data in the interaction of cPDI with TA-core under (A) 50mM AcOH-AcOK
buffer (pH 5.5) and (B) 50 mM AcOH-AcONa buffer (pH 5.5).
Table 3
Binding parameters and of cPDI with TA-core and dsDNA in presence of K+ and Na+.
K+ Na+
DNA TA-Core HP-27 TA-Core HP-27
Configuration Hybrid to antipararell Hairpin Antipararell Hairpin
10−5 Ka/M−1 11.6 – 30.3 –
n 2 – 2 –
ΔH/(kcal/mol) -6.712 – -7.141 –
−TΔS/(kcal/mol) -1.559 – -1.702 –
ΔG25oC/(kcal/mol) -8.271 – -8.843 –
–: Not determined.
Fig. 5. Human topoisomerase I assay.
This clearly indicates that the cPDI does not bind to the double
stranded DNA.
3.6. Evaluation of inhibition of telomerase
After the G-quadruplexes DNA stabilization was recognized for
cPDI, it is very important to test whether the molecule inhibits telom-
erase activity or not. To evaluate the ability of cPDI to inhibit telom-
erase, the telomeric repeat amplification protocol (TRAP assay)30 was
carried out using various amounts of cPDI (Fig. 6A). The assay
clearly shows that cPDI is a powerful inhibitor of telomerase with ac-
tivity in the submicromolar range (IC50) 0.24μM (Fig. 6B). This re-
sult suggests that the TS-primer extends the length to form a tetraplex
structure and cPDI binds to it and stabilizes its structure to inhibit
the telomerase reaction. The values obtained from the TRAP assay
are comparable to those of previously reported G-quadruplex bind-
ing ligands. A number of small ligand have been discovered to in-
hibit the function of telomerase by stabilizing G-quadruplexes DNA
structures.31 The excellent IC50 for telomerase inhibition by cPDI
(0.24 μM) comes from its binding constant. It is suggested that this
cyclic perylenediimide compound cPDI may deserve biological as-
says with cancer cell lines to represent a suitable candidate drug which
can be used as anticancer drug.
4. Conclusions
In conclusion we successfully designed and synthesized a new
cyclic perylenediimide ligand cPDI and studied the interaction of
cPDI with tetraplex TA-core DNA and double stranded. The cyclic
structure of cPDI prevent the traditional aggregation of perylenedi-
imide and favors the formation of J-type aggregation of two cPDI
molecules in between two successive G-tetrads of G-quadruplex
DNA. To estimate the selectivity of the ligand towards tetraplex DNA
over the double stranded DNA we performed the binding studies
with calf thymus DNA (CT-DNA). The binding studies of cPDI have
shown that it has shown the binding constant of 6.3× 106 M−1 with
n= 2 of binding number with TA-core derived from human telomere
DNA sequence and a very low binding constant with double stranded
DNA (CT-DNA). All the studies like CD, ITC and Tm studies were
performed in presence of both K+ and Na+ ions. From CD it has been
observed that in presence and absence of any ion the cPDI favors
the stabilization of antiparallel structure of TA-core. Thermal changes
achieved from ITC experiment confirm cPDI forms a stable complex
with TA-core. From all the studies it has been proven that cPDI does
not associate with dsDNA. Moreover, from TRAP assay we found that
cPDI has the excellent telomere inhibition activity bound to tetraplex
DNA generated from TS-primer with telomerase and stabilized to in-
hibit the telomerase reaction with IC50 value of 0.24µM. Our results
with cPDI as a new class of cyclic ligand, opens a path to design
highly selective and efficient ligands for the regulation of the telom-
erase activity to use as an anticancer drug.
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Fig. 6. Gel electropherogram of TRAP assay in the presence of the varied amount of cPDI.
A. Supplementary data
Supplementary data associated with this article can be found, in the
online version, at https://doi.org/10.1016/j.bmc.2017.10.014.
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